Acute Invasive Aspergillosis Treatment Market Size Share Trends Forecast 2026

SEATTLE - March 8, 2021 - PRLog -- Acute Invasive Aspergillosis Treatment Market Drivers

Rising incidence of various types of cancers, is in turn expected to support growth of the global Acute Invasive Aspergillosis Treatment Market. According to the Centers for Disease Control and Prevention, the epidemiology of invasive aspergillus infection is dependent upon increasing number of solid organ transplants, stem cell transplant, and newer immunosuppressive agents, 2017. According to Organ Procurement and Transplantation Network (OPTN), around 8,500 organ transplants have been performed in 2018 and the number is expected to grow in the near future. These factors are expected to support the growth of the acute invasive aspergillosis treatment market. Patients who undergo organ transplant procedure are often prescribed immunosuppressant medications, which increases their susceptibility to aspergillosis infection. Similarly, patients in the advanced stages of AIDS are also highly susceptible to opportunistic infections such as aspergillosis.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1520

Acute Invasive Aspergillosis is an acute infection or fungal growth, which arises due to Aspergillus fungus. Almost everyone comes in contact with the Aspergillus fungus as it is found on decaying vegetation and dead leaves, however, not everyone is susceptible to the infection.

The U.S. Food & Drug Administration (FDA) is increasingly approving several drugs for the treatment of this infection. For instance, Isavuconazonium, a prodrug form of Isavuconazole was approved by the FDA in 2015. Astellas Pharma US, Inc. markets Isavuconazonium under the brand name Cresemba. Astellas Pharma partnered with Basilea Pharmaceutica International Ltd. for license, co-development, and co-promotion of Isavuconazole (Cresemba), in 2010.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/acute-invasive-aspergillosis-treatment-market-1520

Acute Invasive Aspergillosis Treatment Market Insights

Manufacturers such as Amneal Pharmaceuticals, Sandoz Inc., Glenmark Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., and Teva Pharmaceuticals offer generic versions of antifungal medications in the acute invasive aspergillosis treatment market. Independent organizations are dedicated towards research and development of novel antifungal therapies. For instance, F2G, an established U.K.-based biotechnology company is focused on the discovery and development of novel drugs for the treatment of serious fungal diseases such as acute invasive aspergillosis.

Key players operating in the global acute invasive aspergillosis treatment market include GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott laboratories, Eli Lilly and Company, AstraZeneca Plc, Pfizer, Inc., Johnson & Johnson, Takeda Pharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica International Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1520